WO2024035268A3 - Tau pathway modulators - Google Patents
Tau pathway modulators Download PDFInfo
- Publication number
- WO2024035268A3 WO2024035268A3 PCT/QA2023/050016 QA2023050016W WO2024035268A3 WO 2024035268 A3 WO2024035268 A3 WO 2024035268A3 QA 2023050016 W QA2023050016 W QA 2023050016W WO 2024035268 A3 WO2024035268 A3 WO 2024035268A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau
- pathway modulators
- modulators
- pathway
- methods
- Prior art date
Links
- 230000037361 pathway Effects 0.000 title 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pharmaceutical compositions and methods for treating tauopathies are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263396855P | 2022-08-10 | 2022-08-10 | |
US63/396,855 | 2022-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024035268A2 WO2024035268A2 (en) | 2024-02-15 |
WO2024035268A3 true WO2024035268A3 (en) | 2024-03-21 |
Family
ID=89852244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/QA2023/050016 WO2024035268A2 (en) | 2022-08-10 | 2023-08-09 | Tau pathway modulators |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024035268A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080234384A1 (en) * | 2007-03-19 | 2008-09-25 | Xenon Pharmaceuticals Inc. | Biaryl and biheteroaryl compounds useful in treating iron disorders |
US7902330B2 (en) * | 2004-02-13 | 2011-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Protein kinase inhibitors and methods for identifying same |
KR101830838B1 (en) * | 2015-07-02 | 2018-02-22 | 이화여자대학교 산학협력단 | Pharmaceutical composition comprising peptidomimetic compounds for preventing and treating rheumatoid arthritis |
-
2023
- 2023-08-09 WO PCT/QA2023/050016 patent/WO2024035268A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7902330B2 (en) * | 2004-02-13 | 2011-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Protein kinase inhibitors and methods for identifying same |
US20080234384A1 (en) * | 2007-03-19 | 2008-09-25 | Xenon Pharmaceuticals Inc. | Biaryl and biheteroaryl compounds useful in treating iron disorders |
KR101830838B1 (en) * | 2015-07-02 | 2018-02-22 | 이화여자대학교 산학협력단 | Pharmaceutical composition comprising peptidomimetic compounds for preventing and treating rheumatoid arthritis |
Non-Patent Citations (1)
Title |
---|
DATABASE PubChem ANONYMOUS : "2-(Phenylthio)-benzoic Acid", XP093150836 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024035268A2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074100L (en) | Microplants for ocular administration | |
WO2022031952A3 (en) | Treatments for cancers having kras mutations | |
WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
EP3954380A4 (en) | Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof | |
WO2021004958A3 (en) | Compositions comprising bacterial strains | |
WO2024035268A3 (en) | Tau pathway modulators | |
WO2021024133A3 (en) | Biopharmacuetical compositions and related methods | |
MX2022011576A (en) | Nlrp3 modulators. | |
WO2022032073A3 (en) | Trpml modulators | |
EP3980039A4 (en) | Pharmaceutical composition for preventing or treating atopic disease containingakkermansia muciniphila | |
WO2008153792A3 (en) | Gamma secretase modulators | |
WO2018136596A8 (en) | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide | |
MX2021008941A (en) | Gpr35 modulators. | |
MX2022005388A (en) | Pyrrolidine and piperidine compounds. | |
WO2023240253A3 (en) | Modulators of tnf-alpha activity | |
EP4083037A4 (en) | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same | |
WO2021118924A3 (en) | Compositions and methods for the prevention and treatment of hearing loss | |
WO2020257460A3 (en) | Apj modulators and uses thereof | |
EP4103192A4 (en) | Compositions and methods for treating coronavirus infections | |
EP4114423A4 (en) | Compositions and methods for the treatment of intracellular bacterial infections | |
EP4103177A4 (en) | Compositions and methods for treating and/or preventing ocular disorders | |
EP3964218A4 (en) | Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient | |
EP3995136A4 (en) | Pharmaceutical composition containing tamsulosin or hydrochloride thereof and preparation method therefor | |
FR3093427B1 (en) | COMPOSITION FOR USE IN THE PREVENTION AND / OR TREATMENT OF DYSBIOSIS | |
AU2022903010A0 (en) | Pharmaceutical compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23853121 Country of ref document: EP Kind code of ref document: A2 |